Cocrystal Pharma completes patient enrollment in phase 2a study evaluating CC-31244 for ultra-short treatment of hepatitis C.

Cocrystal, a clinical stage biotechnology company, announced today the completion of patient enrollment in its Phase 2a clinical study evaluating CC-31244 for the ultra-short treatment of hepatitis C virus (HCV)-infected individuals.